يعرض 1 - 12 نتائج من 12 نتيجة بحث عن '"Cotiguala, Laura"', وقت الاستعلام: 0.46s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal

    وصف الملف: application/pdf

    Relation: Cotiguala, Laura; Masood, Ahmad; Park, Jeong M.; Samaniego‐picota, Milagros D.; Kaul, Daniel R.; Naik, Abhijit S. (2021). "Increasing net immunosuppression after BK polyoma virus infection." Transplant Infectious Disease (2): n/a-n/a.; https://hdl.handle.net/2027.42/167446; Transplant Infectious Disease; Schold JD, Rehman S, Kayler LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int. 2009; 22: 626 - 634.; Mbianda C, El- Meanawy A, Sorokin A. Mechanisms of BK virus infection of renal cells and therapeutic implications. J Clin Virol. 2015; 71: 59 - 62.; Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus- associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005; 79: 1277 - 1286.; Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol. 2007; 2: S36 - S46.; Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010; 89: 1057 - 1070.; Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation- Guidelines from the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019; e13528.; Drachenberg CB, Papadimitriou JC, Chaudhry MR, et al. Histological evolution of BK virus- associated nephropathy: importance of integrating clinical and pathological findings. Am J Transplant. 2017; 17: 2078 - 2091.; Nankivell BJ, Renthawa J, Sharma RN, et al. BK virus nephropathy: histological evolution by sequential pathology. Am J Transplant. 2017; 17: 2065 - 2077.; Elfadawy N, Flechner SM, Schold JD, et al. Transient versus persistent BK viremia and long- term outcomes after kidney and kidney- pancreas transplantation. Clin J Am Soc Nephrol. 2014; 9 ( 3 ): 553 - 561.; Dieplinger G, Everly MJ, Briley KP, et al. Onset and progression of de novo donor- specific anti- human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction. Transpl Infect Dis. 2015; 17: 848 - 858.; Devresse A, Tinel C, Vermorel A, et al. No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single- center experience. Transpl Int. 2019; 32: 481 - 492.; Cheungpasitporn W, Kremers WK, Lorenz E, et al. De novo donor- specific antibody following BK nephropathy: the incidence and association with antibody- mediated rejection. Clin Transplant. 2018; 32 ( 3 ): e13194.; Sawinski D, Forde KA, Trofe- Clark J, et al. Persistent BK viremia does not increase intermediate- term graft loss but is associated with de novo donor- specific antibodies. J Am Soc Nephrol. 2015; 26: 966 - 975.; Zhou W, Sharma M, Martinez J, et al. Functional characterization of BK virus- specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol. 2007; 20: 379 - 388.; Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol. 2006; 80 ( 7 ): 3495 - 3505.; Baek CH, Kim H, Yu H, et al. Risk factors of acute rejection in patients with BK nephropathy after reduction of immunosuppression. Ann Transplant. 2018; 23: 704 - 712.; Solez K, Colvin RB, Racusen LC, et al. Banff 07 Classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8: 753 - 760.; Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell- mediated rejection, antibody- mediated rejection, and prospects for integrative endpoints for next- generation clinical trials. Am J Transplant. 2018; 18: 293 - 307.; Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor- specific alloantibody in primary renal allografts. Transplantation. 2013; 95: 410 - 417.; Kasiske BL, Gaston RS, Gourishankar S, et al. Long- term deterioration of kidney allograft function. Am J Transplant. 2005; 5: 1405 - 1414.; Hardinger KL, Koch MJ, Bohl DJ, et al. BK- virus and the impact of pre- emptive immunosuppression reduction: 5- year results. Am J Transplant. 2010; 10: 407 - 415.; Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation. 2008; 85: 850.; Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre- emptive intervention in pediatric kidney recipients. Am J Transplant. 2007; 7: 2727 - 2735.; Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long- term outcomes. Nephrol Dial Transplant. 2019; 34: 1240 - 1250.

  9. 9
    Academic Journal

    وصف الملف: application/pdf

    Relation: Ky, Trung Q.; Park, Jeong M.; McMurry, Katie A.; Tischer, Sarah M.; Fitzgerald, Linda J.; Cotiguala, Laura (2021). "Oropharyngeal candidiasis outcomes in renal transplant recipients receiving nystatin versus no antifungal prophylaxis." Transplant Infectious Disease (3): n/a-n/a.; https://hdl.handle.net/2027.42/168352; Transplant Infectious Disease; Al‐Mohaya MA, Darwazeh A, Al‐Khudair W. Oral fungal colonization and oral candidiasis in renal transplant patients: the relationship to Miswak use. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 93 ( 4 ): 455 ‐ 460.; Sikora MB, Truax C, Lee S, et al. Low‐dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. Clin Transplant. 2012; 26 ( 5 ): 555 – 560.; Dongari‐Bagtzoglou A, Dwivedi P, Ioannidou E, Shaqman M, Hull D, Burleson J. Oral Candida infection and colonization in solid organ transplant recipients. Oral Microbiol Immunol. 2009; 24 ( 3 ): 249 ‐ 254.; Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006; 20 ( 4 ): 401 ‐ 409.; Gombert ME, Dubouchet L, Aulicino TM, Butt KMH. A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants: use in prophylaxis of oropharyngeal candidiasis. JAMA. 1987; 258 ( 18 ): 2553 ‐ 2555.; Gupta KL, Ghosh AK, Kochhar R, Jha V, Chakrabarti A, Sakhuja V. Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols. Am J Gastroenterol. 1994; 89 ( 7 ): 1062 ‐ 1065.; Guerra CM, Formica RN, Kulkarni S, Asch WS, Tichy EM. Duration of prophylaxis against fungal infection in kidney transplant recipients. Prog Transplant. 2015; 25 ( 4 ): 311 ‐ 315.; Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med. 1984; 144 ( 2 ): 290 ‐ 293.; Coronado‐Castellote L, Jiménez‐Soriano Y. Clinical and microbiological diagnosis of oral candidiasis. J Clin Exp Dent. 2013; 5 ( 5 ): 279 ‐ 286.; López‐Pintor RM, Hernández G, de Arriba L, de Andrés A. Oral candidiasis in patients with renal transplants. Med Oral Patol Oral Cir Bucal. 2013; 18 ( 3 ): 381 – 387.; Güleç ATülin, Demirbilek M, Seçkin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case‐control study. J Am Acad Dermatol. 2003; 49 ( 2 ): 187 ‐ 192.; Morales JM, Varo E, Lázaro P. Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain. Clin Transplant. 2012; 26 ( 2 ): 369 ‐ 376.; Chisholm MA. Identification of medication‐adherence barriers and strategies to increase adherence in recipients of renal transplants. Manag Care Interface. 2004; 17: 44.; Chisholm‐Burns MA, Spivey CA, Graff Zivin J, Lee JK, Sredzinski E, Tolley EA. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. Am J Transplant. 2013; 13 ( 9 ): 2364 ‐ 2373.; Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001; 15 ( 2 ): 95 ‐ 99.; Manez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation. 1994; 57 ( 10 ): 1521 ‐ 1523.; Chapman JR. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation. 2010; 89 ( 6 ): 644 ‐ 645.

  10. 10
    Academic Journal
  11. 11
  12. 12
    Academic Journal